Organic Letters
Letter
(3) For a recent review on site-selective functionalization of
halogenated heterocycles using Pd catalysis, see: (a) Fairlamb, I. J.
S. Chem. Soc. Rev. 2007, 36, 1036−1045. For other representative C−
N coupling examples, see: (b) Peng, Z.-H.; Journet, M.; Humphrey,
G. Org. Lett. 2006, 8, 395−398. (c) Keylor, M. H.; Niemeyer, Z. L.;
Sigman, M. S.; Tan, K. L. J. Am. Chem. Soc. 2017, 139, 10613−10616.
(4) ICH Harmonised Tripartite Guideline: Impurities in New Drug
(5) (a) Legault, C. Y.; Garcia, Y.; Merlic, C. A.; Houk, K. N. J. Am.
Chem. Soc. 2007, 129, 12664−12665. (b) Garcia, Y.; Schoenebeck, F.;
Legault, C. Y.; Merlic, C. A.; Houk, K. N. J. Am. Chem. Soc. 2009, 131,
6632−6639.
(6) For selected examples, see: (a) Morgentin, R.; Barlaam, B.;
Foote, K.; Hassall, L.; Hawkins, J.; Jones, C. D.; Le Griffon, A.; Peru,
C-2 amidation, tailoring the order of which the amide reactants
are added allows for indirect selectivity at the 4-position
(compare 5a/b). It should be noted that development of a
highly C-4 selective Pd-catalyzed process on 2,4-dichloropyr-
idine remains an unsolved problem.20
In summary, we have identified a catalyst system that
amidates dichloroazines such as substituted 2,4-dichloropyr-
idines with a high level of C-2 selectivity. The substrate scope
with respect to both amide and dichloroazine is broad, allowing
for the preparation of a diverse series of functionalized hetero-
cycles in good to excellent yields (70−97%). The utility of this
method was further expanded through development of sequential
amidation protocols to form differentially substituted bis-
amidated pyridines. The high level of site-selectivity imparted
by this catalyst system is intriguing from a mechanistic per-
spective, and additional studies will be reported in due course.
́
A.; Ple, P. Synth. Commun. 2012, 42, 8−24. (b) Burton, R. J.;
Crowther, M. L.; Fazakerley, N. J.; Fillery, S. M.; Hayter, B. M.;
Kettle, J. G.; McMillan, C. A.; Perkins, P.; Robins, P.; Smith, P. M.;
Williams, E. J.; Wrigley, G. L. Tetrahedron Lett. 2013, 54, 6900−6904.
(7) Examples from the patent literature utilized Xantphos or t-
BuXPhos derivative ligands which were shown to be suboptimal in
our reaction development: (a) Brown, M.; Chen, Y.; Cushing, T. D.;
Gonzalez Lopez De Turiso, F.; He, X.; Kohn, T. J.; Lohman, J. W.;
Pattaropong, V.; Seganish, J.; Shin, Y.; Simard, J. L. PCT Int. Patent
Appl. WO 2010151737 A2, Dec 29, 2010. (b) Jung, P. J. M.; Lachia,
M. D.; Leipner, J.; Brocklehurst, D.; De Mesmaeker, A.; Wendeborn,
S. V. PCT Int. Patent Appl. WO 2014131732 A2, Sep 4, 2014. (c)
Bronson, J. J.; Chen, L.; Ditta, J. L.; Dzierba, C. D.; Jalagam, P. R.;
Luo, G.; Macor, J. E.; Maishal, T. K.; Nara, S. J.; Rajamani, R.; Sistla,
R. K.; Thangavel, S. PCT Int. Patent Appl. WO 2017059085 A1, Apr
6, 2017.
ASSOCIATED CONTENT
* Supporting Information
The Supporting Information is available free of charge on the
■
S
General experimental procedures, characterization
1
details, and H, 13C, and 19F NMR (PDF)
Single-crystal X-ray reports (PDF)
Accession Codes
tallographic data for this paper. These data can be obtained
Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
(8) Delvare, C.; Koza, P.; Morgentin, R. Synthesis 2011, 2011,
2431−2436.
́
(9) (a) Abad, A.; Agullo, C.; Cunat, A. C.; Vilanova, C. Synthesis
̃
2005, 2005, 915−924. (b) Yule, I. A.; Czaplewski, L. G.; Pommier, S.;
Davies, D. T.; Narramore, S. K.; Fishwick, C. W. G. Eur. J. Med. Chem.
2014, 86, 31−38.
AUTHOR INFORMATION
Corresponding Authors
■
(10) Gordillo, A.; Titlbach, S.; Futter, C.; Lejkowski, M. L.; Prasetyo,
E.; Rupflin, L. T. A.; Emmert, T.; Schunk, S. A. High-Throughput
Experimentation in Catalysis and Materials Science. In Ullmann’s
Encyclopedia of Industrial Chemistry; Wiley-VCH: Weinheim, 2014; pp
1−19.
ORCID
(11) For representative examples, see: (a) Hartwig, J. F.; Kawatsura,
M.; Hauck, S. I.; Shaughnessy, K. H.; Alcazar-Roman, L. M. J. Org.
Chem. 1999, 64, 5575−5580. (b) Yin, J.; Buchwald, S. L. J. Am. Chem.
Soc. 2002, 124, 6043−6048. (c) Huang, X.; Anderson, K. W.; Zim, D.;
Jiang, L.; Klapars, A.; Buchwald, S. L. J. Am. Chem. Soc. 2003, 125,
6653−6655. (d) Klapars, A.; Campos, K. R.; Chen, C.; Volante, R. P.
Org. Lett. 2005, 7, 1185−1188. (e) Hicks, J. D.; Hyde, A. M.; Cuezva,
A. M.; Buchwald, S. L. J. Am. Chem. Soc. 2009, 131, 16720−16734.
(12) Product site selectivities were unambiguously assigned by
obtaining the single-crystal X-ray structure of 3a′ (C-4 product).
(13) Sollot, G. P.; Snead, J. L.; Portnoy, S.; Peterson, W. R., Jr.;
Mertwoy, H. E. Chem. Abstr. 1965, 63, 18147.
(14) (a) Prat, D.; Pardigon, O.; Flemming, H.-W.; Letestu, S.;
Ducandas, V.; Isnard, P.; Guntrum, E.; Senac, T.; Ruisseau, S.;
Cruciani, P.; Hosek, P. Org. Process Res. Dev. 2013, 17, 1517−1525.
(b) Prat, D.; Hayler, J.; Wells, A. Green Chem. 2014, 16, 4546−4551.
(15) In most cases, the reactions were heated overnight to ensure
rates of reaction comparison based on amide/substituted dichlor-
oazine.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank Professor Stephen Buchwald (Massachusetts
Institute of Technology) for helpful discussions, Dr. Antonio
DiPasquale for single-crystal X-ray analysis, and Dr. Kenji
Kurita for collecting HRMS data (Genentech, Inc.).
REFERENCES
■
(1) For a recent review, see: Taylor, A. P.; Robinson, R. P.; Fobian,
Y. M.; Blakemore, D. C.; Jones, L. H.; Fadeyi, O. Org. Biomol. Chem.
2016, 14, 6611−6637.
analysis of compounds 3i, 3j, and 3k could not conclusively
distinguish between C-2 vs C-4 amidation.
analysis of compounds 4h, 4j, and 4m could not conclusively
distinguish between C-2 vs C-4 amidation.
(2) For reviews on Pd- or Cu-catalyzed C−N couplings, see:
(a) Evano, G.; Blanchard, N.; Toumi, M. Chem. Rev. 2008, 108,
3054−3131. (b) Hartwig, J. F. Acc. Chem. Res. 2008, 41, 1534−1544.
(c) Surry, D. S.; Buchwald, S. L. Chem. Sci. 2010, 1, 13−31. (d) Surry,
D. S.; Buchwald, S. L. Chem. Sci. 2011, 2, 27−50. (e) Ruiz-Castillo, P.;
Buchwald, S. L. Chem. Rev. 2016, 116, 12564−12649.
D
Org. Lett. XXXX, XXX, XXX−XXX